The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Infantile Spasms Therapeutics Market Research Report 2024

Global Infantile Spasms Therapeutics Market Research Report 2024

Publishing Date : Jan, 2024

License Type :
 

Report Code : 1418810

No of Pages : 75

Ask Your Query

Synopsis

An infantile spasm (IS), also known as West Syndrome, is a specific type of seizure seen in an epilepsy syndrome of infancy and childhood. West Syndrome is characterized by infantile spasms, developmental regression, and a specific pattern on electroencephalography (EEG) testing called hypsarrhythmia (chaotic brain waves). The onset of infantile spasms is usually in the first year of life, typically between 4-8 months. The seizures primarily consist of a sudden bending forward of the body with stiffening of the arms and legs; some children arch their backs as they extend their arms and legs. The condition is usually observed in 2% of childhood epilepsies and 25% of epilepsies that start in the first year of life.

The global Infantile Spasms Therapeutics market was valued at US$ 142 million in 2023 and is anticipated to reach US$ 182.4 million by 2030, witnessing a CAGR of 3.6% during the forecast period 2024-2030.

Global Infantile Spasms Therapeutics key players include Mallinckrodt, H. Lundbeck, etc. Global top two manufacturers hold a share over 60%.

In terms of product, Oral is the largest segment, with a share obout 55%. And in terms of application, the largest application is Hospital, followed by Clinic, etc.

This report aims to provide a comprehensive presentation of the global market for Infantile Spasms Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Infantile Spasms Therapeutics.

Report Scope

The Infantile Spasms Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Infantile Spasms Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Infantile Spasms Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

By Company

  • Mallinckrodt
  • H. Lundbeck
  • Insys Therapeutics
  • Orphelia Pharma
  • Valerion Therapeutics
  • Catalyst Pharmaceuticals
  • Anavex Life Sciences
  • Retrophin
  • GW Pharmaceuticals

Segment by Type

  • Oral
  • Injection

Segment by Application

  • Hospital
  • Clinic
  • Other

By Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Infantile Spasms Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Infantile Spasms Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Oral
1.2.3 Injection
1.3 Market by Application
1.3.1 Global Infantile Spasms Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Infantile Spasms Therapeutics Market Perspective (2019-2030)
2.2 Infantile Spasms Therapeutics Growth Trends by Region
2.2.1 Global Infantile Spasms Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Infantile Spasms Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Infantile Spasms Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Infantile Spasms Therapeutics Market Dynamics
2.3.1 Infantile Spasms Therapeutics Industry Trends
2.3.2 Infantile Spasms Therapeutics Market Drivers
2.3.3 Infantile Spasms Therapeutics Market Challenges
2.3.4 Infantile Spasms Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Infantile Spasms Therapeutics Players by Revenue
3.1.1 Global Top Infantile Spasms Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Infantile Spasms Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Infantile Spasms Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Infantile Spasms Therapeutics Revenue
3.4 Global Infantile Spasms Therapeutics Market Concentration Ratio
3.4.1 Global Infantile Spasms Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Infantile Spasms Therapeutics Revenue in 2023
3.5 Infantile Spasms Therapeutics Key Players Head office and Area Served
3.6 Key Players Infantile Spasms Therapeutics Product Solution and Service
3.7 Date of Enter into Infantile Spasms Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Infantile Spasms Therapeutics Breakdown Data by Type
4.1 Global Infantile Spasms Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Infantile Spasms Therapeutics Forecasted Market Size by Type (2025-2030)
5 Infantile Spasms Therapeutics Breakdown Data by Application
5.1 Global Infantile Spasms Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Infantile Spasms Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Infantile Spasms Therapeutics Market Size (2019-2030)
6.2 North America Infantile Spasms Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Infantile Spasms Therapeutics Market Size by Country (2019-2024)
6.4 North America Infantile Spasms Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Infantile Spasms Therapeutics Market Size (2019-2030)
7.2 Europe Infantile Spasms Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Infantile Spasms Therapeutics Market Size by Country (2019-2024)
7.4 Europe Infantile Spasms Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Infantile Spasms Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Infantile Spasms Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Infantile Spasms Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Infantile Spasms Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Infantile Spasms Therapeutics Market Size (2019-2030)
9.2 Latin America Infantile Spasms Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Infantile Spasms Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Infantile Spasms Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Infantile Spasms Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Infantile Spasms Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Infantile Spasms Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Infantile Spasms Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Mallinckrodt
11.1.1 Mallinckrodt Company Detail
11.1.2 Mallinckrodt Business Overview
11.1.3 Mallinckrodt Infantile Spasms Therapeutics Introduction
11.1.4 Mallinckrodt Revenue in Infantile Spasms Therapeutics Business (2019-2024)
11.1.5 Mallinckrodt Recent Development
11.2 H. Lundbeck
11.2.1 H. Lundbeck Company Detail
11.2.2 H. Lundbeck Business Overview
11.2.3 H. Lundbeck Infantile Spasms Therapeutics Introduction
11.2.4 H. Lundbeck Revenue in Infantile Spasms Therapeutics Business (2019-2024)
11.2.5 H. Lundbeck Recent Development
11.3 Insys Therapeutics
11.3.1 Insys Therapeutics Company Detail
11.3.2 Insys Therapeutics Business Overview
11.3.3 Insys Therapeutics Infantile Spasms Therapeutics Introduction
11.3.4 Insys Therapeutics Revenue in Infantile Spasms Therapeutics Business (2019-2024)
11.3.5 Insys Therapeutics Recent Development
11.4 Orphelia Pharma
11.4.1 Orphelia Pharma Company Detail
11.4.2 Orphelia Pharma Business Overview
11.4.3 Orphelia Pharma Infantile Spasms Therapeutics Introduction
11.4.4 Orphelia Pharma Revenue in Infantile Spasms Therapeutics Business (2019-2024)
11.4.5 Orphelia Pharma Recent Development
11.5 Valerion Therapeutics
11.5.1 Valerion Therapeutics Company Detail
11.5.2 Valerion Therapeutics Business Overview
11.5.3 Valerion Therapeutics Infantile Spasms Therapeutics Introduction
11.5.4 Valerion Therapeutics Revenue in Infantile Spasms Therapeutics Business (2019-2024)
11.5.5 Valerion Therapeutics Recent Development
11.6 Catalyst Pharmaceuticals
11.6.1 Catalyst Pharmaceuticals Company Detail
11.6.2 Catalyst Pharmaceuticals Business Overview
11.6.3 Catalyst Pharmaceuticals Infantile Spasms Therapeutics Introduction
11.6.4 Catalyst Pharmaceuticals Revenue in Infantile Spasms Therapeutics Business (2019-2024)
11.6.5 Catalyst Pharmaceuticals Recent Development
11.7 Anavex Life Sciences
11.7.1 Anavex Life Sciences Company Detail
11.7.2 Anavex Life Sciences Business Overview
11.7.3 Anavex Life Sciences Infantile Spasms Therapeutics Introduction
11.7.4 Anavex Life Sciences Revenue in Infantile Spasms Therapeutics Business (2019-2024)
11.7.5 Anavex Life Sciences Recent Development
11.8 Retrophin
11.8.1 Retrophin Company Detail
11.8.2 Retrophin Business Overview
11.8.3 Retrophin Infantile Spasms Therapeutics Introduction
11.8.4 Retrophin Revenue in Infantile Spasms Therapeutics Business (2019-2024)
11.8.5 Retrophin Recent Development
11.9 GW Pharmaceuticals
11.9.1 GW Pharmaceuticals Company Detail
11.9.2 GW Pharmaceuticals Business Overview
11.9.3 GW Pharmaceuticals Infantile Spasms Therapeutics Introduction
11.9.4 GW Pharmaceuticals Revenue in Infantile Spasms Therapeutics Business (2019-2024)
11.9.5 GW Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock